RPL22L1 and neoplasm: Because no commercial antibodies against RPL22 or RPL22L1 gave reliable IHC results in patient tumor samples, we developed an anti-human RPL22L1 polyclonal antibody and verified its specificity and its function in immunoblotting, immunofluorescent staining, and immunohistochemistry (S3 Fig).